Press Release Description

Global Autoimmune Disorder Drug Delivery Devices Market is likely to grow at a CAGR of 15.25% in the forecast period of 2021-26

According to MarkNtel Advisors' research report, "Global Autoimmune Disorder Drug Delivery Devices Market Analysis, 2021," the market is likely to grow at a CAGR of 15.25% during 2021-26. There are multiple supporting factors behind the robust growth of the market. Healthcare professionals have discovered the autoimmune disorders sector as one of the most rapidly evolving markets due to the increasing incidence of chronic diseases, global population, and growing demand for self-injectable systems.

Key questions answered in the study

  1. What are the current and future trends in the Global Autoimmune Disorder Drug Delivery Devices Market?
  2. How has the industry been evolving in terms of geography and services adoption?
  3. How has the competition been shaping across the countries, followed by their comparative factorial indexing?
  4. What are the key growth drivers & challenges for the Global Autoimmune Disorder Drug Delivery Devices Market?
  5. What is the customer orientation, purchase behavior, and expectations from the Global Autoimmune Disorder Drug Delivery Devices Market service providers across various regions?

Pen-Injectors to Witness Fastest Growth

Based on the Product Type, the Global Autoimmune Disorder Drug Delivery Devices Market segments into Pen-Injectors, Auto-Injectors, Pre-Filled Syringes, Vials. Of all, the Pen-Injectors are more likely to witness the fastest growth in the forecast years. It owes prominently to the growing prevalence of chronic diseases and the favorable reimbursement scenario in multiple countries. Furthermore, the increasing preference for biosimilar drugs is another determinant enabling the market to create lucrative growth opportunities for key players in the Global Autoimmune Disorder Drug Delivery Devices Market during the forecast period of 2021-26.

"Global Autoimmune Disorder Drug Delivery Devices Market Analysis, 2021" provides comprehensive, qualitative, and quantitative insights on the market potential, key factors impacting the market growth, hotspots, and opportunities available for Autoimmune Disorder Drug Delivery Devices providers across the globe. Moreover, the report also encompasses the key strategic imperatives for competitors' success and strategic factorial indexing to measure their capabilities on 16 parameters, which will help companies formulate 'Go to Market' strategies and identify the blue ocean for their offerings. 

North America to Attain Fastest Growth

The Global Autoimmune Disorder Drug Delivery Devices Market is expanding throughout the globe. However, when it comes to the region, North America is very consistent in attaining the fastest growth in the forecast period of 2021-26. It owes primarily to the constantly improving healthcare infrastructure, rising per capita income, and the availability of state-of-the-art research laboratories & institutions in the region. Furthermore, the exponential rise in the adoption of self-injection devices to treat autoimmune disorders is creating a trend and gaining popularity among numerous companies to invest in the research & development of novel autoimmune disorder drug delivery devices. Therefore, North America is very likely to contribute to the overall market growth in the forecast period, reveals MarkNtel Advisors in their research report, "Global Autoimmune Disorder Drug Delivery Devices Market Analysis, 2021."

According to MarkNtel Advisors, the leading players in the Global Autoimmune Disorder Drug Delivery Devices Market are Amgen Inc., AbbVie Inc., Bayer AG, Biogen Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Hoffmann-La Roche AG, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., The Merck Group, Novartis International AG, Sanofi SA, Teva Pharmaceutical Industries Ltd., UCB Pharma SA.

Market Segmentation:

  1. By Indications (Psoriasis, Rheumatoid Arthritis, Multiple Sclerosis, Inflammatory Bowel Diseases, Systemic Lupus Erythematosus, Diabetes Mellitus, Others (Guillain Barre Syndrome, Grave’s Disease, etc.))
  2. By Product Type (Pen-Injectors, Auto-Injectors, Pre-Filled Syringes, Vials)
  3. By Manufacturing Type (In-House Manufacturing, Outsourced Manufacturing)
  4. By Region (North America, South America, Europe, Asia-Pacific, Middle East, and Africa)
  5. By Competitors (Amgen Inc., AbbVie Inc., Bayer AG, Biogen Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Hoffmann-La Roche AG, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., The Merck Group, Novartis International AG, Sanofi SA, Teva Pharmaceutical Industries Ltd., UCB Pharma SA)